...sepsis-associated-acute kidney injury (see “AM-Pharma Raises €116M Series C” ). Zucara raises $21M A round Zucara Therapeutics Inc....
...dropped HK$2.35 to HK$28.95 in Hong Kong on Tuesday. Targets SSTR2 - Somatostatin receptor 2 BioCentury Staff Zucara Therapeutics Inc. AM-Pharma...

...its lead therapy with a pharma partner after demonstrating clinical proof of concept. COMPANY PROFILE Zucara Therapeutics Inc....
...B.C. MaRS Innovation, Toronto, Ontario Tulane University, New Orleans, La. University of Toronto, Toronto, Ontario Zucara Therapeutics Inc....
...hypoglycemic diabetic rats.” Diabetes (2013) Virginia Li, Staff Writer Centre for Drug Research and Development MaRS Innovation University of Toronto Zucara Therapeutics Inc. Somatostatin...

...CDRD declined to disclose financial terms. Centre for Drug Research and Development , Vancouver, B.C. Zucara Therapeutics Inc....

...thereafter. For CDRD, the deal builds on a successful 1H16, which saw the spin-out of Zucara Therapeutics Inc....
...by Zymeworks Inc. Source: BCIQ: BioCentury Online Intelligence; CDRD website Date Company Description October 2016 Zucara Therapeutics Inc....
...Calif. University of Minnesota, Minneapolis, Minn. University of Sussex, Falmer, U.K. Wellcome Trust, London, U.K. Zucara Therapeutics Inc....